SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001829126-24-000082
Filing Date
2024-01-08
Accepted
2024-01-08 17:13:45
Documents
13
Period of Report
2024-01-08
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K titanpharma_8k.htm   iXBRL 8-K 28804
2 EXHIBIT 3.1 titanpharma_ex3-1.htm EX-3.1 10962
  Complete submission text file 0001829126-24-000082.txt   217910

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE ttnp-20240108.xsd EX-101.SCH 3021
4 XBRL LABEL FILE ttnp-20240108_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE ttnp-20240108_pre.xml EX-101.PRE 22363
7 EXTRACTED XBRL INSTANCE DOCUMENT titanpharma_8k_htm.xml XML 3435
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

IRS No.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-13341 | Film No.: 24521024
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)